Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
Reviews in Endocrine and Metabolic Disorders
Erschienen in: Reviews in Endocrine and Metabolic Disorders 1/2016

09.03.2016

Cardiometabolic crosstalk in obesity-associated arterial hypertension

verfasst von: Jens Jordan, Andreas L. Birkenfeld

Erschienen in: Reviews in Endocrine and Metabolic Disorders | Ausgabe 1/2016

Einloggen, um Zugang zu erhalten

Abstract

Abdominal obesity and elevated blood pressure commonly occur in the same patient and are key components of the metabolic syndrome. However, the association between obesity and increased blood pressure is variable. We review mechanisms linking cardiovascular and metabolic disease in such patients including altered systemic and regional hemodynamic control, neurohumoral activation, and relative natriuretic peptide deficiency. Moreover, we discuss recent results using omics techniques providing insight in molecular pathways linking adiposity, metabolic disease, and arterial hypertension. Recognition of the mechanisms orchestrating the crosstalk between cardiovascular and metabolic regulation in individual patients may lead to better and more precise treatments. It is reassuring that recently developed cardiovascular and metabolic medications may in fact ameliorate, both, cardiovascular and metabolic risks.
Literatur
1.
Bramlage P, Pittrow D, Wittchen HU, Kirch W, Boehler S, Lehnert H, et al. Hypertension in overweight and obese primary care patients is highly prevalent and poorly controlled. Am J Hypertens. 2004;17(10):904–10.PubMedCrossRef
2.
Wilson PW, D’Agostino RB, Sullivan L, Parise H, Kannel WB. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med. 2002;162(16):1867–72.PubMedCrossRef
3.
Must A, Spadano J, Coakley EH, Field AE, Colditz G, Dietz WH. The disease burden associated with overweight and obesity. JAMA. 1999;282(16):1523–9.PubMedCrossRef
4.
Doll S, Paccaud F, Bovet P, Burnier M, Wietlisbach V. Body mass index, abdominal adiposity and blood pressure: consistency of their association across developing and developed countries. Int J Obes Relat Metab Disord. 2002;26(1):48–57.PubMedCrossRef
5.
Wyatt SB, Akylbekova EL, Wofford MR, Coady SA, Walker ER, Andrew ME, et al. Prevalence, awareness, treatment, and control of hypertension in the Jackson Heart Study. Hypertension. 2008;51(3):650–6.PubMedCrossRef
6.
Bruce MA, Beech BM, Griffith DM, Thorpe Jr RJ. Weight status and blood pressure among adolescent African American males: the Jackson Heart KIDS Pilot Study. Ethn Dis. 2015;25(3):305–12.PubMedCrossRef
7.
Jordan J, Yumuk V, Schlaich M, Nilsson PM, Zahorska-Markiewicz B, Grassi G, et al. Joint statement of the European Association for the Study of Obesity and the European Society of Hypertension: obesity and difficult to treat arterial hypertension. J Hypertens. 2012;30(6):1047–55.PubMedCrossRef
8.
Lloyd-Jones DM, Evans JC, Larson MG, O’donnell CJ, Roccella EJ, Levy D. Differential control of systolic and diastolic blood pressure : factors associated with lack of blood pressure control in the community. Hypertension. 2000;36(4):594–9.PubMedCrossRef
9.
Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, Grimm RH, et al. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich). 2002;4(6):393–404.CrossRef
10.
Egan BM, Zhao Y, Axon RN, Brzezinski WA, Ferdinand KC. Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008. Circulation. 2011;124:1046–58.PubMedPubMedCentralCrossRef
11.
Weyer C, Pratley RE, Snitker S, Spraul M, Ravussin E, Tataranni PA. Ethnic differences in insulinemia and sympathetic tone as links between obesity and blood pressure. Hypertension. 2000;36(4):531–7.PubMedCrossRef
12.
Meigs JB, D’Agostino Sr RB, Wilson PW, Cupples LA, Nathan DM, Singer DE. Risk variable clustering in the insulin resistance syndrome. the Framingham Offspring Study. Diabetes. 1997;46(10):1594–600.PubMedCrossRef
13.
Chen W, Srinivasan SR, Elkasabany A, Berenson GS. Cardiovascular risk factors clustering features of insulin resistance syndrome (Syndrome X) in a biracial (Black-White) population of children, adolescents, and young adults: the Bogalusa Heart Study. Am J Epidemiol. 1999;150(7):667–74.PubMedCrossRef
14.
Valkonen VP, Kolehmainen M, Lakka HM, Salonen JT. Insulin resistance syndrome revisited: application of self-organizing maps. Int J Epidemiol. 2002;31(4):864–71.PubMedCrossRef
15.
Jordan J, Engeli S, Redon J, Sharma AM, Luft FC, Narkiewicz K, et al. European Society of Hypertension Working Group on Obesity: background, aims and perspectives. J Hypertens. 2007;25(4):897–900.PubMedCrossRef
16.
Messerli FH, Christie B, DeCarvalho JG, Aristimuno GG, Suarez DH, Dreslinski GR, et al. Obesity and essential hypertension. hemodynamics, intravascular volume, sodium excretion, and plasma renin activity. Arch Intern Med. 1981;141(1):81–5.PubMedCrossRef
17.
de Divitiis O, Fazio S, Petitto M, Maddalena G, Contaldo F, Mancini M. Obesity and cardiac function. Circulation. 1981;64(3):477–82.PubMedCrossRef
18.
Licata G, Scaglione R, Barbagallo M, Parrinello G, Capuana G, Lipari R, et al. Effect of obesity on left ventricular function studied by radionuclide angiocardiography. Int J Obes. 1991;15(4):295–302.PubMed
19.
Hall JE, Brands MW, Dixon WN, Smith Jr MJ. Obesity-induced hypertension. renal function and systemic hemodynamics. Hypertension. 1993;22(3):292–9.PubMedCrossRef
20.
Mujais SK, Tarazi RC, Dustan HP, Fouad FM, Bravo EL. Hypertension in obese patients: hemodynamic and volume studies. Hypertension. 1982;4(1):84–92.PubMedCrossRef
21.
Raison JM, Safar ME, Cambien FA, London GM. Forearm haemodynamics in obese normotensive and hypertensive subjects. J Hypertens. 1988;6(4):299–303.PubMedCrossRef
22.
Limberg JK, Kellawan JM, Harrell JW, Johansson RE, Eldridge MW, Proctor LT, et al. Exercise-mediated vasodilation in human obesity and metabolic syndrome: effect of acute ascorbic acid infusion. Am J Physiol Heart Circ Physiol. 2014;307(6):H840–7.PubMedPubMedCentralCrossRef
23.
Lucas PD, Foy JM. Effects of experimental diabetes and genetic obesity on regional blood flow in the rat. Diabetes. 1977;26(8):786–92.PubMedCrossRef
24.
Baron AD, Laakso M, Brechtel G, Hoit B, Watt C, Edelman SV. Reduced postprandial skeletal muscle blood flow contributes to glucose intolerance in human obesity. J Clin Endocrinol Metab. 1990;70(6):1525–33.PubMedCrossRef
25.
Tibblin G, Bergentz SE, Bjure J, Wilhelmsen L. Hematocrit, plasma protein, plasma volume, and viscosity in early hypertensive disease. Am Heart J. 1966;72(2):165–76.PubMedCrossRef
26.
Sandhagen B, Frithz G, Waern U, Ronquist G. Increased whole blood viscosity combined with decreased erythrocyte fluidity in untreated patients with essential hypertension. J Intern Med. 1990;228(6):623–6.PubMedCrossRef
27.
Levy Y, Elias N, Cogan U, Yeshurun D. Abnormal erythrocyte rheology in patients with morbid obesity. Angiology. 1993;44(9):713–7.PubMedCrossRef
28.
Messerli FH. Cardiovascular effects of obesity and hypertension. Lancet. 1982;1(8282):1165–8.PubMedCrossRef
29.
Karaca U, Schram MT, Houben AJ, Muris DM, Stehouwer CD. Microvascular dysfunction as a link between obesity, insulin resistance and hypertension. Diabetes Res Clin Pract. 2014;103(3):382–7.PubMedCrossRef
30.
Wofford MR, Anderson Jr DC, Brown CA, Jones DW, Miller ME, Hall JE. Antihypertensive effect of alpha- and beta-adrenergic blockade in obese and lean hypertensive subjects. Am J Hypertens. 2001;14(7 Pt 1):694–8.PubMedCrossRef
31.
Shannon JR, Jordan J, Diedrich A, Pohar B, Black BK, Robertson D, et al. Sympathetically mediated hypertension in autonomic failure. Circulation. 2000;101:2710–5.PubMedCrossRef
32.
Shibao C, Gamboa A, Diedrich A, Ertl AC, Chen KY, Byrne DW, et al. Autonomic contribution to blood pressure and metabolism in obesity. Hypertension. 2007;49(1):27–33.PubMedCrossRef
33.
Grassi G, Seravalle G, Cattaneo BM, Bolla GB, Lanfranchi A, Colombo M, et al. Sympathetic activation in obese normotensive subjects. Hypertension. 1995;25(4 Pt 1):560–3.PubMedCrossRef
34.
Grassi G, Seravalle G, Dell’Oro R, Turri C, Bolla GB, Mancia G. Adrenergic and reflex abnormalities in obesity-related hypertension. Hypertension. 2000;36(4):538–42.PubMedCrossRef
35.
Rumantir MS, Vaz M, Jennings GL, Collier G, Kaye DM, Seals DR, et al. Neural mechanisms in human obesity-related hypertension. J Hypertens. 1999;17(8):1125–33.PubMedCrossRef
36.
Rahmouni K, Haynes WG, Mark AL. Cardiovascular and sympathetic effects of leptin. Curr Hypertens Rep. 2002;4(2):119–25.PubMedCrossRef
37.
Hall JE, Da Silva AA, do Carmo JM, Dubinion J, Hamza S, Munusamy S. Obesity-induced hypertension: role of sympathetic nervous system, leptin, and melanocortins. J Biol Chem. 2010;285(23):17271–6.PubMedPubMedCentralCrossRef
38.
Greenfield JR, Miller JW, Keogh JM, Henning E, Satterwhite JH, Cameron GS, et al. Modulation of blood pressure by central melanocortinergic pathways. N Engl J Med. 2009;360(1):44–52.PubMedCrossRef
39.
Ozata M, Ozdemir IC, Licinio J. Human leptin deficiency caused by a missense mutation: multiple endocrine defects, decreased sympathetic tone, and immune system dysfunction indicate new targets for leptin action, greater central than peripheral resistance to the effects of leptin, and spontaneous correction of leptin-mediated defects. J Clin Endocrinol Metab. 1999;84(10):3686–95.PubMedCrossRef
40.
Goncalves AC, Tank J, Diedrich A, Hilzendeger A, Plehm R, Bader M, et al. Diabetic hypertensive leptin receptor-deficient db/db mice develop cardioregulatory autonomic dysfunction. Hypertension. 2009;53(2):387–92.PubMedCrossRef
41.
Grassi G, Facchini A, Trevano FQ, Dell’Oro R, Arenare F, Tana F, et al. Obstructive sleep apnea-dependent and -independent adrenergic activation in obesity. Hypertension. 2005;46(2):321–5.PubMedCrossRef
42.
Narkiewicz K, van de Borne PJH, Cooley RL, Dyken ME, Somers VK. Sympathetic activity in obese subjects with and without obstructive sleep apnea. Circulation. 1998;98(8):772–6.PubMedCrossRef
43.
Jamerson KA, Julius S, Gudbrandsson T, Andersson O, Brant DO. Reflex sympathetic activation induces acute insulin resistance in the human forearm. Hypertension. 1993;21(5):618–23.PubMedCrossRef
44.
Grassi G, Seravalle G, Quarti-Trevano F, Scopelliti F, Dell’Oro R, Bolla G, et al. Excessive sympathetic activation in heart failure with obesity and metabolic syndrome: characteristics and mechanisms. Hypertension. 2007;49(3):535–41.PubMedCrossRef
45.
Seravalle G, Colombo M, Perego P, Giardini V, Volpe M, Dell’Oro R, et al. Long-term sympathoinhibitory effects of surgically induced weight loss in severe obese patients. Hypertension. 2014;64(2):431–7.PubMedCrossRef
46.
Straznicky NE, Lambert EA, Grima MT, Eikelis N, Richards K, Nestel PJ, et al. The effects of dietary weight loss on indices of norepinephrine turnover: modulatory influence of hyperinsulinemia. Obesity (Silver Spring). 2014;22(3):652–62.CrossRef
47.
Straznicky NE, Grima MT, Eikelis N, Nestel PJ, Dawood T, Schlaich MP, et al. The effects of weight loss versus weight loss maintenance on sympathetic nervous system activity and metabolic syndrome components. J Clin Endocrinol Metab. 2011;96(3):E503–8.PubMedCrossRef
48.
Tuck ML, Sowers J, Dornfeld L, Kledzik G, Maxwell M. The effect of weight reduction on blood pressure, plasma renin activity, and plasma aldosterone levels in obese patients. N Engl J Med. 1981;304(16):930–3.PubMedCrossRef
49.
Engeli S, Boschmann M, Frings P, Beck L, Janke J, Titze J, et al. Influence of salt intake on renin-angiotensin and natriuretic peptide system genes in human adipose tissue. Hypertension. 2006;48(6):1103–8.PubMedCrossRef
50.
Ehrhart-Bornstein M, Lamounier-Zepter V, Schraven A, Langenbach J, Willenberg HS, Barthel A, et al. Human adipocytes secrete mineralocorticoid-releasing factors. Proc Natl Acad Sci U S A. 2003;100(24):14211–6.PubMedPubMedCentralCrossRef
51.
Vleugels K, Schinner S, Krause D, Morawietz H, Bornstein SR, Ehrhart-Bornstein M, et al. ERK1/2 MAPKs and Wnt signaling pathways are independently involved in adipocytokine-mediated aldosterone secretion. Exp Clin Endocrinol Diabetes. 2011;119(10):644–8.PubMedCrossRef
52.
Engeli S, Bohnke J, Gorzelniak K, Janke J, Schling P, Bader M, et al. Weight loss and the renin-angiotensin-aldosterone system. Hypertension. 2005;45(3):356–62.PubMedCrossRef
53.
O’Seaghdha CM, Hwang SJ, Vasan RS, Larson MG, Hoffmann U, Wang TJ, et al. Correlation of renin angiotensin and aldosterone system activity with subcutaneous and visceral adiposity: the framingham heart study. BMC Endocr Disord. 2012;12:3.PubMedPubMedCentralCrossRef
54.
55.
Zhou MS, Schulman IH, Raij L. Role of angiotensin II and oxidative stress in vascular insulin resistance linked to hypertension. Am J Physiol Heart Circ Physiol. 2009;296(3):H833–9.PubMedCrossRef
56.
Zhou MS, Liu C, Tian R, Nishiyama A, Raij L. Skeletal muscle insulin resistance in salt-sensitive hypertension: role of angiotensin II activation of NFkappaB. Cardiovasc Diabetol. 2015;14:45.PubMedPubMedCentralCrossRef
57.
Grassi G, Dell’Oro R, Quarti-Trevano F, Scopelliti F, Seravalle G, Paleari F, et al. Neuroadrenergic and reflex abnormalities in patients with metabolic syndrome. Diabetologia. 2005;48(7):1359–65.PubMedCrossRef
58.
Straznicky NE, Grima MT, Sari CI, Eikelis N, Lambert EA, Nestel PJ, et al. Neuroadrenergic dysfunction along the diabetes continuum: a comparative study in obese metabolic syndrome subjects. Diabetes. 2012;61(10):2506–16.PubMedPubMedCentralCrossRef
59.
Anderson EA, Hoffman RP, Balon TW, Sinkey CA, Mark AL. Hyperinsulinemia produces both sympathetic neural activation and vasodilation in normal humans. J Clin Invest. 1991;87(6):2246–52.PubMedPubMedCentralCrossRef
60.
Haenni A, Lithell H. Moxonidine improves insulin sensitivity in insulin-resistant hypertensives. J Hypertens Suppl. 1999;17(3):S29–35.PubMed
61.
Gamboa A, Okamoto LE, Arnold AC, Figueroa RA, Diedrich A, Raj SR, et al. Autonomic blockade improves insulin sensitivity in obese subjects. Hypertension. 2014;64(4):867–74.PubMedPubMedCentralCrossRef
62.
Gomes ME, Mulder A, Bellersen L, Verheugt FW, Smits P, Tack CJ. Alpha-receptor blockade improves muscle perfusion and glucose uptake in heart failure. Eur J Heart Fail. 2010;12(10):1061–6.PubMedPubMedCentralCrossRef
63.
Lind L, Eriksson M. Influence of nervous blockade on insulin-mediated glucose uptake in the human forearm. Metabolism. 2003;52(4):413–7.PubMedCrossRef
64.
Heusser K, Tank J, Engeli S, Diedrich A, Menne J, Eckert S, et al. Carotid baroreceptor stimulation, sympathetic activity, baroreflex function, and blood pressure in hypertensive patients. Hypertension. 2010;55(3):619–26.PubMedCrossRef
65.
Heusser K, Tank J, Brinkmann J, Menne J, Kaufeld J, Linnenweber-Held S, et al. Acute response to unilateral unipolar electrical carotid sinus stimulation in patients with resistant arterial hypertension. Hypertension. 2016.
66.
May M, Ahrens J, Menne J, Haller H, Beige J, Eckert S, et al. Limited acute influences of electrical baroreceptor activation on insulin sensitivity and glucose delivery: a randomized, double-blind, cross-over clinical study. Diabetes. 2014.
67.
Zeng W, Pirzgalska RM, Pereira MM, Kubasova N, Barateiro A, Seixas E, et al. Sympathetic neuro-adipose connections mediate leptin-driven lipolysis. Cell. 2015;163(1):84–94.PubMedCrossRef
68.
Laurila PP, Soronen J, Kooijman S, Forsstrom S, Boon MR, Surakka I, et al. USF1 deficiency activates brown adipose tissue and improves cardiometabolic health. Sci Transl Med. 2016;8(323):323ra13.PubMedCrossRef
69.
Hanssen MJ, van der Lans AA, Brans B, Hoeks J, Jardon KM, Schaart G, et al. Short-term cold acclimation recruits brown adipose tissue in obese humans. Diabetes. 2015.
70.
Vijgen GH, Bouvy ND, Teule GJ, Brans B, Schrauwen P, van Marken Lichtenbelt WD. Brown adipose tissue in morbidly obese subjects. PLoS One. 2011;6(2):e17247.PubMedPubMedCentralCrossRef
71.
Yoneshiro T, Aita S, Matsushita M, Okamatsu-Ogura Y, Kameya T, Kawai Y, et al. Age-related decrease in cold-activated brown adipose tissue and accumulation of body fat in healthy humans. Obesity (Silver Spring). 2011;19(9):1755–60.CrossRef
72.
Blondin DP, Labbe SM, Noll C, Kunach M, Phoenix S, Guerin B, et al. Selective impairment of glucose but not fatty acid or oxidative metabolism in brown adipose tissue of subjects with type 2 diabetes. Diabetes. 2015;64(7):2388–97.PubMedCrossRef
73.
Kingma BR, Frijns AJ, Saris WH, van Steenhoven AA, Lichtenbelt WD. Increased systolic blood pressure after mild cold and rewarming: relation to cold-induced thermogenesis and age. Acta Physiol (Oxf). 2011;203(4):419–27.CrossRef
74.
Colussi G, Catena C, Lapenna R, Nadalini E, Chiuch A, Sechi LA. Insulin resistance and hyperinsulinemia are related to plasma aldosterone levels in hypertensive patients. Diabetes Care. 2007;30(9):2349–54.PubMedCrossRef
75.
Catena C, Lapenna R, Baroselli S, Nadalini E, Colussi G, Novello M, et al. Insulin sensitivity in patients with primary aldosteronism: a follow-up study. J Clin Endocrinol Metab. 2006;91(9):3457–63.PubMedCrossRef
76.
Habibi J, Whaley-Connell A, Hayden MR, DeMarco VG, Schneider R, Sowers SD, et al. Renin inhibition attenuates insulin resistance, oxidative stress, and pancreatic remodeling in the transgenic Ren2 rat. Endocrinology. 2008;149(11):5643–53.PubMedPubMedCentralCrossRef
77.
Vettor R, Cusin I, Ganten D, Rohner-Jeanrenaud F, Ferrannini E, Jeanrenaud B. Insulin resistance and hypertension: studies in transgenic hypertensive TGR(mREN-2)27 rats. Am J Physiol. 1994;267(6 Pt 2):R1503–9.PubMed
78.
Bonnet F, Patel S, Laville M, Balkau B, Favuzzi A, Monti LD, et al. Influence of the ACE gene insertion/deletion polymorphism on insulin sensitivity and impaired glucose tolerance in healthy subjects. Diabetes Care. 2008;31(4):789–94.PubMedCrossRef
79.
Petrie JR, Morris AD, Ueda S, Small M, Donnelly R, Connell JM, et al. Trandolapril does not improve insulin sensitivity in patients with hypertension and type 2 diabetes: a double-blind, placebo-controlled crossover trial. J Clin Endocrinol Metab. 2000;85(5):1882–9.PubMed
80.
van der Zijl NJ, Moors CC, Goossens GH, Hermans MM, Blaak EE, Diamant M. Valsartan improves {beta}-cell function and insulin sensitivity in subjects with impaired glucose metabolism: a randomized controlled trial. Diabetes Care. 2011;34(4):845–51.PubMedPubMedCentralCrossRef
81.
Maack T, Suzuki M, Almeida FA, Nussenzveig D, Scarborough RM, McEnroe GA, et al. Physiological role of silent receptors of atrial natriuretic factor. Science. 1987;238(4827):675–8.PubMedCrossRef
82.
Sarzani R, Dessi-Fulgheri P, Paci VM, Espinosa E, Rappelli A. Expression of natriuretic peptide receptors in human adipose and other tissues. J Endocrinol Invest. 1996;19(9):581–5.PubMedCrossRef
83.
Kenny AJ, Bourne A, Ingram J. Hydrolysis of human and pig brain natriuretic peptides, urodilatin, C-type natriuretic peptide and some C-receptor ligands by endopeptidase-24.11. Biochem J. 1993;291(Pt 1):83–8.PubMedPubMedCentralCrossRef
84.
Morabito D, Vallotton MB, Lang U. Obesity is associated with impaired ventricular protein kinase C-MAP kinase signaling and altered ANP mRNA expression in the heart of adult Zucker rats. J Investig Med. 2001;49(4):310–8.PubMedCrossRef
85.
Khan AM, Cheng S, Magnusson M, Larson MG, Newton-Cheh C, McCabe EL, et al. Cardiac natriuretic peptides, obesity, and insulin resistance: evidence from two community-based studies. J Clin Endocrinol Metab. 2011;96(10):3242–9.PubMedPubMedCentralCrossRef
86.
Licata G, Volpe M, Scaglione R, Rubattu S. Salt-regulating hormones in young normotensive obese subjects. Effects of saline load. Hypertension. 1994;23(1 Suppl):I20–I4.PubMedCrossRef
87.
Dessi-Fulgheri P, Sarzani R, Tamburrini P, Moraca A, Espinosa E, Cola G, et al. Plasma atrial natriuretic peptide and natriuretic peptide receptor gene expression in adipose tissue of normotensive and hypertensive obese patients. J Hypertens. 1997;15(12 Pt 2):1695–9.PubMedCrossRef
88.
Nakatsuji H, Maeda N, Hibuse T, Hiuge A, Hirata A, Kuroda Y, et al. Reciprocal regulation of natriuretic peptide receptors by insulin in adipose cells. Biochem Biophys Res Commun. 2010;392(1):100–5.PubMedCrossRef
89.
Floras JS. Sympathoinhibitory effects of atrial natriuretic factor in normal humans. Circulation. 1990;81(6):1860–73.PubMedCrossRef
90.
Brunner-La Rocca HP, Kaye DM, Woods RL, Hastings J, Esler MD. Effects of intravenous brain natriuretic peptide on regional sympathetic activity in patients with chronic heart failure as compared with healthy control subjects. J Am Coll Cardiol. 2001;37(5):1221–7.PubMedCrossRef
91.
Asferg CL, Nielsen SJ, Andersen UB, Linneberg A, Moller DV, Hedley PL, et al. Relative atrial natriuretic peptide deficiency and inadequate renin and angiotensin II suppression in obese hypertensive men. Hypertension. 2013;62(1):147–53.PubMedCrossRef
92.
Dessi-Fulgheri P, Sarzani R, Serenelli M, Tamburrini P, Spagnolo D, Giantomassi L, et al. Low calorie diet enhances renal, hemodynamic, and humoral effects of exogenous atrial natriuretic peptide in obese hypertensives. Hypertension. 1999;33(2):658–62.PubMedCrossRef
93.
Haufe S, Kaminski J, Utz W, Haas V, Mahler A, Daniels MA, et al. Differential response of the natriuretic peptide system to weight loss and exercise in overweight or obese patients. J Hypertens. 2015;33(7):1458–64.PubMedCrossRef
94.
Lafontan M, Moro C, Berlan M, Crampes F, Sengenes C, Galitzky J. Control of lipolysis by natriuretic peptides and cyclic GMP. Trends Endocrinol Metab. 2008;19(4):130–7.PubMedCrossRef
95.
Sengenes C, Bouloumie A, Hauner H, Berlan M, Busse R, Lafontan M, et al. Involvement of a cGMP-dependent pathway in the natriuretic peptide-mediated hormone-sensitive lipase phosphorylation in human adipocytes. J Biol Chem. 2003;278(49):48617–26.PubMedCrossRef
96.
Birkenfeld AL, Boschmann M, Moro C, Adams F, Heusser K, Franke G, et al. lipid mobilization with physiological atrial natriuretic peptide concentrations in humans. J Clin Endocrinol Metab. 2005;90:3622–8.PubMedCrossRef
97.
Birkenfeld AL, Budziarek P, Boschmann M, Moro C, Adams F, Franke G, et al. Atrial natriuretic peptide induces postprandial lipid oxidation in humans. Diabetes. 2008;57(12):3199–204.PubMedPubMedCentralCrossRef
98.
Engeli S, Birkenfeld AL, Badin PM, Bourlier V, Louche K, Viguerie N, et al. Natriuretic peptides enhance the oxidative capacity of human skeletal muscle. J Clin Invest. 2012;122(12):4675–9.PubMedPubMedCentralCrossRef
99.
Bordicchia M, Liu D, Amri EZ, Ailhaud G, ssi-Fulgheri P, Zhang C. Cardiac natriuretic peptides act via p38 MAPK to induce the brown fat thermogenic program in mouse and human adipocytes. J Clin Invest. 2012;122(3):1022–36.PubMedPubMedCentralCrossRef
100.
Birkenfeld AL, Boschmann M, Engeli S, Moro C, Arafat AM, Luft FC, et al. Atrial natriuretic peptide and adiponectin interactions in man. PLoS One. 2012;7(8):e43238.PubMedPubMedCentralCrossRef
101.
Miyashita K, Itoh H, Tsujimoto H, Tamura N, Fukunaga Y, Sone M, et al. Natriuretic peptides/cGMP/cGMP-dependent protein kinase cascades promote muscle mitochondrial biogenesis and prevent obesity. Diabetes. 2009;58(12):2880–92.PubMedPubMedCentralCrossRef
102.
Coue M, Badin PM, Vila IK, Laurens C, Louche K, Marques MA, et al. Defective natriuretic peptide receptor signaling in skeletal muscle links obesity to type 2 diabetes. Diabetes. 2015.
103.
Magnusson M, Jujic A, Hedblad B, Engstrom G, Persson M, Struck J, et al. Low plasma level of atrial natriuretic peptide predicts development of diabetes: the prospective Malmo Diet and Cancer study. J Clin Endocrinol Metab. 2012;97(2):638–45.PubMedPubMedCentralCrossRef
104.
Hoffmann LS, Etzrodt J, Willkomm L, Sanyal A, Scheja L, Fischer AW, et al. Stimulation of soluble guanylyl cyclase protects against obesity by recruiting brown adipose tissue. Nat Commun. 2015;6:7235.PubMedPubMedCentralCrossRef
105.
Nyberg M, Piil P, Egelund J, Sprague RS, Mortensen SP, Hellsten Y et al. Potentiation of cGMP signaling increases oxygen delivery and oxidative metabolism in contracting skeletal muscle of older but not young humans. Physiol Rep. 2015; 3 (8).
106.
Newton-Cheh C, Larson MG, Vasan RS, Levy D, Bloch KD, Surti A, et al. Association of common variants in NPPA and NPPB with circulating natriuretic peptides and blood pressure. Nat Genet. 2009;41(3):348–53.PubMedPubMedCentralCrossRef
107.
Arora P, Wu C, Khan AM, Bloch DB, vis-Dusenbery BN, Ghorbani A. Atrial natriuretic peptide is negatively regulated by microRNA-425. J Clin Invest. 2013;123(8):3378–82.PubMedPubMedCentralCrossRef
108.
Vodovar N, Seronde MF, Laribi S, Gayat E, Lassus J, Boukef R, et al. Post-translational modifications enhance NT-proBNP and BNP production in acute decompensated heart failure. Eur Heart J. 2014;35(48):3434–41.PubMedCrossRef
109.
Jujic A, Nilsson PM, Engstrom G, Hedblad B, Melander O, Magnusson M. Atrial natriuretic peptide and type 2 diabetes development--biomarker and genotype association study. PLoS One. 2014;9(2):e89201.PubMedPubMedCentralCrossRef
110.
Schlueter N, De SA, Willmes DM, Spranger J, Jordan J, Birkenfeld AL. Metabolic actions of natriuretic peptides and therapeutic potential in the metabolic syndrome. Pharmacol Ther. 2014;144(1):12–27.PubMedCrossRef
111.
Cheng S, Rhee EP, Larson MG, Lewis GD, McCabe EL, Shen D, et al. Metabolite profiling identifies pathways associated with metabolic risk in humans. Circulation. 2012;125(18):2222–31.PubMedPubMedCentralCrossRef
112.
Greenfield JR, Farooqi IS, Keogh JM, Henning E, Habib AM, Blackwood A, et al. Oral glutamine increases circulating glucagon-like peptide 1, glucagon, and insulin concentrations in lean, obese, and type 2 diabetic subjects. Am J Clin Nutr. 2009;89(1):106–13.PubMedPubMedCentralCrossRef
113.
Addabbo F, Chen Q, Patel DP, Rabadi M, Ratliff B, Zhang F, et al. Glutamine supplementation alleviates vasculopathy and corrects metabolic profile in an in vivo model of endothelial cell dysfunction. PLoS One. 2013;8(6):e65458.PubMedPubMedCentralCrossRef
114.
Yaghootkar H, Scott RA, White CC, Zhang W, Speliotes E, Munroe PB, et al. Genetic evidence for a normal-weight “metabolically obese” phenotype linking insulin resistance, hypertension, coronary artery disease, and type 2 diabetes. Diabetes. 2014;63(12):4369–77.PubMedPubMedCentralCrossRef
115.
Rankinen T, Sarzynski MA, Ghosh S, Bouchard C. Are there genetic paths common to obesity, cardiovascular disease outcomes, and cardiovascular risk factors? Circ Res. 2015;116(5):909–22.PubMedPubMedCentralCrossRef
116.
Kristiansson K, Perola M, Tikkanen E, Kettunen J, Surakka I, Havulinna AS, et al. Genome-wide screen for metabolic syndrome susceptibility Loci reveals strong lipid gene contribution but no evidence for common genetic basis for clustering of metabolic syndrome traits. Circ Cardiovasc Genet. 2012;5(2):242–9.PubMedPubMedCentralCrossRef
117.
Schupp M, Janke J, Clasen R, Unger T, Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation. 2004;109(17):2054–7.PubMedCrossRef
118.
Janke J, Schupp M, Engeli S, Gorzelniak K, Boschmann M, Sauma L, et al. Angiotensin type 1 receptor antagonists induce human in-vitro adipogenesis through peroxisome proliferator-activated receptor-gamma activation. J Hypertens. 2006;24(9):1809–16.PubMedCrossRef
119.
Jordan J, Engeli S, Boye SW, Le Breton S, Keefe DL. Direct Renin inhibition with aliskiren in obese patients with arterial hypertension. Hypertension. 2007;49(5):1047–55.PubMedCrossRef
120.
Boschmann M, Nussberger J, Engeli S, Danser AH, Yeh CM, Prescott MF, et al. Aliskiren penetrates adipose and skeletal muscle tissue and reduces renin-angiotensin system activity in obese hypertensive patients. J Hypertens. 2012;30(3):561–6.PubMedCrossRef
121.
McMurray JJ, Holman RR, Haffner SM, Bethel MA, Holzhauer B, Hua TA, et al. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med. 2010;362(16):1477–90.PubMedCrossRef
122.
Bosch J, Yusuf S, Gerstein HC, Pogue J, Sheridan P, Dagenais G, et al. Effect of ramipril on the incidence of diabetes. N Engl J Med. 2006;355(15):1551–62.PubMedCrossRef
123.
McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993–1004.PubMedCrossRef
124.
Ruilope LM, Dukat A, Bohm M, Lacourciere Y, Gong J, Lefkowitz MP. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet. 2010;375(9722):1255–66.PubMedCrossRef
125.
Engeli S, Jordan J. Blood pressure effects of glucagon-like peptide 1 analogues and sodium glucose transporter 2 inhibitors. Curr Opin Nephrol Hypertens. 2014;23(5):468–72.PubMedCrossRef
126.
Goodwill AG, Mather KJ, Conteh AM, Sassoon DJ, Noblet JN, Tune JD. Cardiovascular and hemodynamic effects of glucagon-like peptide-1. Rev Endocr Metab Disord. 2014;15(3):209–17.PubMedPubMedCentralCrossRef
127.
Kanai Y, Lee WS, You G, Brown D, Hediger MA. The human kidney low affinity Na+/glucose cotransporter SGLT2. delineation of the major renal reabsorptive mechanism for D-glucose. J Clin Invest. 1994;93(1):397–404.PubMedPubMedCentralCrossRef
128.
Jurczak MJ, Lee HY, Birkenfeld AL, Jornayvaz FR, Frederick DW, Pongratz RL, et al. SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function. Diabetes. 2011;60(3):890–8.PubMedPubMedCentralCrossRef
129.
Santer R, Kinner M, Lassen CL, Schneppenheim R, Eggert P, Bald M, et al. Molecular analysis of the SGLT2 gene in patients with renal glucosuria. J Am Soc Nephrol. 2003;14(11):2873–82.PubMedCrossRef
130.
Ferrannini E, DeFronzo RA. Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes. Eur Heart J. 2015;36(34):2288–96.PubMedCrossRef
131.
Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–28.PubMedCrossRef
132.
Robinson LE, Holt TA, Rees K, Randeva HS, O’Hare JP. Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis. BMJ Open. 2013;3:e001986.PubMedPubMedCentral
133.
Katout M, Zhu H, Rutsky J, Shah P, Brook RD, Zhong J, et al. Effect of GLP-1 mimetics on blood pressure and relationship to weight loss and glycemia lowering: results of a systematic meta-analysis and meta-regression. Am J Hypertens. 2014;27(1):130–9.PubMedCrossRef
134.
Kim M, Platt MJ, Shibasaki T, Quaggin SE, Backx PH, Seino S, et al. GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure. Nat Med. 2013;19(5):567–75.PubMedCrossRef
135.
Lovshin JA, Barnie A, DeAlmeida A, Logan A, Zinman B, Drucker DJ. Liraglutide promotes natriuresis but does not increase circulating levels of atrial natriuretic peptide in hypertensive subjects with type 2 diabetes. Diabetes Care. 2015;38(1):132–9.PubMedCrossRef
136.
Yamamoto H, Lee CE, Marcus JN, Williams TD, Overton JM, Lopez ME, et al. Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J Clin Invest. 2002;110(1):43–52.PubMedPubMedCentralCrossRef
137.
Ussher JR, Drucker DJ. Cardiovascular actions of incretin-based therapies. Circ Res. 2014;114(11):1788–803.PubMedCrossRef
138.
Pyke C, Heller RS, Kirk RK, Orskov C, Reedtz-Runge S, Kaastrup P, et al. GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody. Endocrinology. 2014;155(4):1280–90.PubMedCrossRef
139.
Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med. 2015;372(9):793–5.PubMedCrossRef
Metadaten
Titel
Cardiometabolic crosstalk in obesity-associated arterial hypertension
verfasst von
Jens Jordan
Andreas L. Birkenfeld
Publikationsdatum
09.03.2016
Verlag
Springer US
Erschienen in
Reviews in Endocrine and Metabolic Disorders / Ausgabe 1/2016
Print ISSN: 1389-9155
Elektronische ISSN: 1573-2606
DOI
https://doi.org/10.1007/s11154-016-9348-1

Weitere Artikel der Ausgabe 1/2016

Reviews in Endocrine and Metabolic Disorders 1/2016 Zur Ausgabe

ReviewPaper

The metabolic vascular syndrome - guide to an individualized treatment

ReviewPaper

Glucose variability, HbA1c and microvascular complications

ReviewPaper

Near normal HbA1c with stable glucose homeostasis: the ultimate target/aim of diabetes therapy

ReviewPaper

Determinants of mortality in patients with type 2 diabetes: a review

ReviewPaper

Interventional treatment of obesity and diabetes: An interim report on gastric electrical stimulation

EditorialNotes

Introduction to Hanefeld Symposium: 40+ years of metabolic syndrome

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

19.04.2024 | Vorhofflimmern | Nachrichten

Parodontalbehandlung verbessert Prognose bei Katheterablation

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Prostatakarzinom: EU initiiert neues Screeningkonzept

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Blasenkarzinom – Biomarker statt Zytologie?

18.04.2024 | Arterielle Hypertonie | Nachrichten

Antihypertensiva schützen auch alte Menschen noch vor Demenz
weitere anzeigen

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise